Zolbetuximab: a potential breakthrough in the treatment landscape of gastric cancer

Rebecca Ibrahim; Khalil Saleh; Rita Khoury; Nadine Khalife; Claude Chahine; Axel Le Cesne

doi:10.2217/fon-2023-0523

Zolbetuximab: a potential breakthrough in the treatment landscape of gastric cancer

Rebecca Ibrahim, Khalil Saleh, Rita Khoury, Nadine Khalife, Claude Chahine, Axel Le Cesne

Résultats de recherche: Contribution à un journal › Editorial

langue originale	Anglais
Pages (de - à)	55-58
Nombre de pages	4
journal	Future Oncology
Volume	20
Numéro de publication	2
Les DOIs	https://doi.org/10.2217/fon-2023-0523
état	Publié - 1 janv. 2024
Modification externe	Oui

Accès au document

10.2217/fon-2023-0523

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{d417a5dbf6eb439b915b279a80442829,

title = "Zolbetuximab: a potential breakthrough in the treatment landscape of gastric cancer",

keywords = "HER2, cldn 18.2, gastric cancer, gastro-esophageal carcinoma, nivolumab, targeted therapy, zolbetuximab",

author = "Rebecca Ibrahim and Khalil Saleh and Rita Khoury and Nadine Khalife and Claude Chahine and {Le Cesne}, Axel",

year = "2024",

month = jan,

day = "1",

doi = "10.2217/fon-2023-0523",

language = "English",

volume = "20",

pages = "55--58",

journal = "Future Oncology",

issn = "1479-6694",

number = "2",

}

TY - JOUR

T1 - Zolbetuximab

T2 - a potential breakthrough in the treatment landscape of gastric cancer

AU - Ibrahim, Rebecca

AU - Saleh, Khalil

AU - Khoury, Rita

AU - Khalife, Nadine

AU - Chahine, Claude

AU - Le Cesne, Axel

PY - 2024/1/1

Y1 - 2024/1/1

KW - HER2

KW - cldn 18.2

KW - gastric cancer

KW - gastro-esophageal carcinoma

KW - nivolumab

KW - targeted therapy

KW - zolbetuximab

UR - http://www.scopus.com/inward/record.url?scp=85184516502&partnerID=8YFLogxK

U2 - 10.2217/fon-2023-0523

DO - 10.2217/fon-2023-0523

M3 - Editorial

C2 - 38193281

AN - SCOPUS:85184516502

SN - 1479-6694

VL - 20

SP - 55

EP - 58

JO - Future Oncology

JF - Future Oncology

IS - 2

ER -